Perioperative Modifikation der Dauermedikation bei kardiovaskulären, pulmonalen und metabolischen Erkrankungen

 

 Buy Article Permissions and Reprints

Zusammenfassung

Ein großer und weiter zunehmender Anteil der Patienten, die sich dem Anästhesisten im Rahmen der Prämedikationsvisite vorstellen, nimmt täglich Medikamente zur Therapie oder Prophylaxe kardiovaskulärer, pulmonaler und/oder metabolischer Erkrankungen ein. Viele dieser Medikamente können in der perioperativen Phase pausiert werden. In manchen Fällen kann das präoperative Absetzen aber auch zur Dekompensation zuvor kompensierter Erkrankungen führen. Ziel dieses Fortbildungsartikels ist es, dem Leser eine Entscheidungshilfe für das Absetzen oder Weiterverordnen der präoperativen Dauermedikation bei kardiovaskulären, pulmonalen und metabolischen Erkrankungen an die Hand zu geben.

Abstract

Almost 50 % of all patients that are evaluated preoperatively by an anesthesiologist are receiving concurrent medication. Many of the prescribed drugs can be omitted during the perioperative period. However, perioperative cessation of certain drug therapies may cause decompensation of primarily compensated diseases. After reading this CME article, the reader should be able to decide whether any cardiovascular, pulmonary or antidiabetic drug therapy should be continued or ceased during the perioperative period, respectively.

Kernaussagen

• Alle Substanzen zur Therapie der KHK, zur Prophylaxe von Angina–Pectoris–Anfällen und für Therapie oder Prophylaxe bronchialer Obstruktionen sollen perioperativ weiter verordnet werden. Hierzu zählen β–Blocker, α₂–Agonisten, Ca⁺⁺–Antagonisten, Nitrate, Statine sowie inhalative β₂–Sympathomimitika, Anticholinergika und Kortikosteroide.

• Innerhalb von 12 Monate nach Einsetzen eines Drug–Eluting–Stents und 4 Wochen nach Einsetzen eines Bare–Metal–Stents darf eine Thienopyridin–Therapie nicht unterbrochen werden. Elektive Eingriffe werden verschoben, bis die Thienopyridin–Therapie abgesetzt werden kann.

• ASS wird bei Zustand nach instabilem Koronarsyndrom und nach kürzlich implantierten Koronarstents nur abgesetzt, wenn das Risiko der erhöhten intraoperativen Blutungsneigung gegenüber dem Risiko einer aufgehobenen Thrombozytenaggregationshemmung überwiegt. In allen anderen Fällen soll niedrigdosiertes ASS perioperativ weiter verordnet werden.

• Rückenmarksnahe Regionalanästhesieverfahren können unter Einnahme von niedrigdosiertem ASS durchgeführt werden, wenn keine gleichzeitige Heparinisierung erfolgt.

• Über die perioperative Verordnung von ACE–Hemmern, AT₁–Blockern und Diuretika muss im Einzelfall entschieden werden.

• Orale Antidiabetika werden mindestens 12 Stunden vor einem operativen Eingriff abgesetzt, um perioperative Hypoglykämien zu vermeiden. Biguanide werden 48 h vor einem operativen Eingriff abgesetzt. Gegebenenfalls wird präoperativ eine Insulin–Therapie begonnen.

Literaturverzeichnis

• 1 Duthie DJ, Montgomery JN, Spence AA, Nimmo WS.. Concurrent drug therapy in patients undergoing surgery.  Anaesthesia. 1987;  42 305-6
  CrossrefPubMedGoogle Scholar
• 2 Wyld R, Nimmo WS.. Do patients fasting before and after operation receive their prescribed drug treatment?.  Br Med J (Clin Res Ed). 1988;  296 744
  PubMedGoogle Scholar
• 3 Kennedy JM, van Rij AM, Spears GF, Pettigrew RA, Tucker IG.. Polypharmacy in a general surgical unit and consequences of drug withdrawal.  Br J Clin Pharmacol. 2000;  49 353-62
  CrossrefPubMedGoogle Scholar
• 4 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-53
  CrossrefPubMedGoogle Scholar
• 5 Hunt SA. et al. . ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.  Circulation. 2001;  104 2996-3007
  CrossrefPubMedGoogle Scholar
• 6 Dietz R, Rauch B.. (Guidelines for diagnosis and treatment of chronic coronary heart disease. Issued by the executive committee of the German Society of Cardiology––Heart Circulation Research in cooperation with the German Society for Prevention and Rehabilitation of Cardiac Diseases and the German Society for Thoracic and Cardiovascular Surgery).  Z Kardiol. 2003;  92 501-21
  PubMedGoogle Scholar
• 7 Glaab T, Weiss T.. (Use of beta blockers in cardiovascular diseases and bronchial asthma/COPD).  Internist (Berl). 2004;  45 221-7
  CrossrefPubMedGoogle Scholar
• 8 Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM.. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group.  N Engl J Med. 1990;  323 1781-8
  CrossrefPubMedGoogle Scholar
• 9 Poldermans D. et al. . The effect of bisoprolol on perioperative mortality and myocardial infarction in high–risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.  N Engl J Med. 1999;  341 1789-94
  CrossrefPubMedGoogle Scholar
• 10 Mangano DT, Layug EL, Wallace A, Tateo I.. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.  N Engl J Med. 1996;  335 1713-20
  CrossrefPubMedGoogle Scholar
• 11 Wallace A. et al. . Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group.  Anesthesiology. 1998;  88 7-17
  PubMedGoogle Scholar
• 12 Poldermans D. et al. . Bisoprolol reduces cardiac death and myocardial infarction in high–risk patients as long as 2 years after successful major vascular surgery.  Eur Heart J. 2001;  22 1353-8
  CrossrefPubMedGoogle Scholar
• 13 Frishman WH.. Beta–drenergic blocker withdrawal.  Am J Cardiol. 1987;  59
  PubMedGoogle Scholar
• 14 Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE.. Perioperative beta–blocker withdrawal and mortality in vascular surgical patients.  Am Heart J. 2001;  141 148-53
  CrossrefPubMedGoogle Scholar
• 15 Lange M. et al. . Role of the beta1–adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo.  Anesthesiology. 2006;  105 503-10
  CrossrefPubMedGoogle Scholar
• 16 Fleisher LA. et al. . ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta–blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology.  Circulation. 2006;  113 2662-74
  CrossrefPubMedGoogle Scholar
• 17 Dahlof B. et al. . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
  CrossrefPubMedGoogle Scholar
• 18 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.. Effects of an angiotensin–converting–enzyme inhibitor, ramipril, on cardiovascular events in high–risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med. 2000;  342 145-53
  CrossrefPubMedGoogle Scholar
• 19 Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S.. Angiotensin–converting–enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.  Lancet. 2006;  368 581-8
  CrossrefPubMedGoogle Scholar
• 20 Hou FF. et al. . Efficacy and safety of benazepril for advanced chronic renal insufficiency.  N Engl J Med. 2006;  354 131-40
  CrossrefPubMedGoogle Scholar
• 21 Maschio G. et al. . Effect of the angiotensin–converting–enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin–Converting–Enzyme Inhibition in Progressive Renal Insufficiency Study Group.  N Engl J Med. 1996;  334 939-45
  CrossrefPubMedGoogle Scholar
• 22 Pfeffer MA. et al. . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.  N Engl J Med. 2003;  349 1893-906
  CrossrefPubMedGoogle Scholar
• 23 Coriat P. et al. . Influence of chronic angiotensin–converting enzyme inhibition on anesthetic induction.  Anesthesiology. 1994;  81 299-307
  CrossrefPubMedGoogle Scholar
• 24 Colson P, Saussine M, Seguin JR, Cuchet D, Chaptal PA, Roquefeuil B.. Hemodynamic effects of anesthesia in patients chronically treated with angiotensin–converting enzyme inhibitors.  Anesth Analg. 1992;  74 805-8
  PubMedGoogle Scholar
• 25 Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P.. Should the angiotensin II antagonists be discontinued before surgery?.  Anesth Analg. 2001;  92 26-30
  PubMedGoogle Scholar
• 26 Licker M. et al. . Long–term angiotensin–converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery.  Anesthesiology. 1996;  84 789-800
  CrossrefPubMedGoogle Scholar
• 27 Ryckwaert F, Colson P.. Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin–converting enzyme inhibitors.  Anesth Analg. 1997;  84 945-9
  CrossrefPubMedGoogle Scholar
• 28 Colson P, Ryckwaert F, Coriat P.. Renin angiotensin system antagonists and anesthesia.  Anesth Analg. 1999;  89 1143-55
  PubMedGoogle Scholar
• 29 Meersschaert K. et al. . Terlipressin–ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensin converting–enzyme inhibitors: a prospective, randomized, double–blinded, crossover study.  Anesth Analg. 2002;  94
  PubMedGoogle Scholar
• 30 Brabant SM, Bertrand M, Eyraud D, Darmon PL, Coriat P.. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists.  Anesth Analg. 1999;  89 1388-92
  CrossrefPubMedGoogle Scholar
• 31 Wijeysundera DN, Naik JS, Beattie WS.. Alpha–2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta–analysis.  Am J Med. 2003;  114 742-52
  CrossrefPubMedGoogle Scholar
• 32 Wallace AW.. Clonidine and modification of perioperative outcome.  Curr Opin Anaesthesiol. 2006;  19 411-7
  CrossrefPubMedGoogle Scholar
• 33 Stevens RD, Burri H, Tramer MR.. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review.  Anesth Analg. 2003;  97 623-33
  PubMedGoogle Scholar
• 34 Perioperative sympatholysis. Beneficial effects of the alpha 2–adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. McSPI––Europe Research Group.  Anesthesiology. 1997;  86 346-63
  PubMedGoogle Scholar
• 35 Stuhmeier KD, Mainzer B, Cierpka J, Sandmann W, Tarnow J.. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery.  Anesthesiology. 1996;  85 706-12
  PubMedGoogle Scholar
• 36 Bruce DL, Croley TF, Lee JS.. Preoperative clonidine withdrawal syndrome.  Anesthesiology. 1979;  51 90-2
  CrossrefPubMedGoogle Scholar
• 37 Karachalios GN. et al. . Withdrawal syndrome following cessation of antihypertensive drug therapy.  Int J Clin Pract. 2005;  59 562-70
  CrossrefPubMedGoogle Scholar
• 38 Tuomilehto J. et al. . Effects of calcium–channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.  N Engl J Med. 1999;  340 677-84
  CrossrefPubMedGoogle Scholar
• 39 Staessen JA. et al. . Randomised double–blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst–Eur) Trial Investigators.  Lancet. 1997;  350 757-64
  CrossrefPubMedGoogle Scholar
• 40 Smith MS, Muir H, Hall R.. Perioperative management of drug therapy, clinical considerations.  Drugs. 1996;  51 238-59
  CrossrefPubMedGoogle Scholar
• 41 Quist L Christensen, Bonde J, Kampmann JP.. Drug interactions with intravenous and local anaesthetics.  Acta Anaesthesiol Scand. 1994;  38 15-29
  PubMedGoogle Scholar
• 42 Goldstein S, Amar D.. Pharmacotherapeutic considerations in anesthesia.  Heart Dis. 2003;  5 34-48
  PubMedGoogle Scholar
• 43 Martsevich SY, Koutishenko N, Metelitsa VI.. Abrupt cessation of short–term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris.  Heart. 1996;  75 447-50
  CrossrefPubMedGoogle Scholar
• 44 Fusciardi J, Godet G, Bernard JM, Bertrand M, Kieffer E, Viars P.. Roles of fentanyl and nitroglycerin in prevention of myocardial ischemia associated with laryngoscopy and tracheal intubation in patients undergoing operations of short duration.  Anesth Analg. 1986;  65 617-24
  PubMedGoogle Scholar
• 45 Dodds TM, Stone JG, Coromilas J, Weinberger M, Levy DG. Prophylactic nitroglycerin infusion during noncardiac surgery does not reduce perioperative ischemia. Anesth Analg 1993: 705-13
  Google Scholar
• 46 Wallner T, Preis C, Mayer N.. Cardiac medication in the perioperative period.  Acta Anaesthesiol Scand Suppl. 1997;  111 22-8
  PubMedGoogle Scholar
• 47 Gibbs NM, Weightman WM, Thackray NM, Michalopoulos N, Weidmann C.. The effects of recent aspirin ingestion on platelet function in cardiac surgical patients.  J Cardiothorac Vasc Anesth. 2001;  15 55-9
  CrossrefPubMedGoogle Scholar
• 48 Burger W, Chemnitius JM, Kneissl GD, Rucker G.. Low–dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta–analysis.  J Intern Med. 2005;  257 399-414
  CrossrefPubMedGoogle Scholar
• 49 Ferrari E, Benhamou M, Cerboni P, Marcel B.. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.  J Am Coll Cardiol. 2005;  45 456-9
  CrossrefPubMedGoogle Scholar
• 50 Collet JP. et al. . Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.  Circulation. 2004;  110 2361-7
  CrossrefPubMedGoogle Scholar
• 51 Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L.. Long–term outcomes with drug–eluting stents versus bare–metal stents in Sweden.  N Engl J Med. 2007;  356 1009-19
  CrossrefPubMedGoogle Scholar
• 52 Stafford–Smith M.. Impaired haemostasis and regional anaesthesia.  Can J Anaesth. 1996;  43 129-41
  PubMedGoogle Scholar
• 53 CLASP: a randomised trial of low–dose aspirin for the prevention and treatment of pre–eclampsia among 9364 pregnant women. CLASP (Collaborative Low–dose Aspirin Study in Pregnancy) Collaborative Group.  Lancet. 1994;  343 619-29
  CrossrefPubMedGoogle Scholar
• 54 Horlocker TT. et al. . Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia.  Anesth Analg. 1995;  80 303-9
  CrossrefPubMedGoogle Scholar
• 55 Horlocker TT. et al. . Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection.  Anesth Analg. 2002;  95
  PubMedGoogle Scholar
• 56 Grines CL. et al. . Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.  Circulation. 2007;  115 813-8
  CrossrefPubMedGoogle Scholar
• 57 Weber AA, Schror K.. (Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid).  Internist (Berl). 1997;  38
  PubMedGoogle Scholar
• 58 Denninger MH, Necciari J, Serre–Lacroix E, Sissmann J.. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.  Semin Thromb Hemost. 1999;  25 2;  41-5
  PubMedGoogle Scholar
• 59 CAPRIE Steering Committee. . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-39
  CrossrefPubMedGoogle Scholar
• 60 Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG.. Melagatran, an oral active–site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.  J Cardiovasc Pharmacol. 1998;  31 345-51
  CrossrefPubMedGoogle Scholar
• 61 Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T.. Impact of clopidogrel in coronary artery bypass grafting.  Eur J Cardiothorac Surg. 2004;  26 96-101
  CrossrefPubMedGoogle Scholar
• 62 Kapetanakis EI. et al. . Effect of clopidogrel premedication in off–pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?.  Circulation. 2006;  113 1667-74
  CrossrefPubMedGoogle Scholar
• 63 Purkayastha S. et al. . Does clopidogrel affect outcome after coronary artery bypass grafting? A meta–analysis.  Heart. 2006;  92 531-2
  PubMedGoogle Scholar
• 64 Wilson SH. et al. . Clinical outcome of patients undergoing non–cardiac surgery in the two months following coronary stenting.  J Am Coll Cardiol. 2003;  42 234-40
  CrossrefPubMedGoogle Scholar
• 65 Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H.. Coronary artery stenting and non–cardiac surgery– prospective outcome study.  Br J Anaesth. 2006;  96 686-93
  CrossrefPubMedGoogle Scholar
• 66 Silber S, Borggrefe M, Böhm M, Hoffmeister H, Dietz R, Ertl G, Heusch G. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents. Der Kardiologe 2007: 84-111
  Google Scholar
• 67 Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal–epidural anesthesia. Anesth Analg 1994: 1165-77
  Google Scholar
• 68 Shepherd J. et al. . Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;  360 1623-30
  CrossrefPubMedGoogle Scholar
• 69 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-9
  PubMedGoogle Scholar
• 70 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long–Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.  N Engl J Med. 1998;  339 1349-57
  CrossrefPubMedGoogle Scholar
• 71 Plehn JF. et al. . Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.  Circulation. 1999;  99 216-23
  PubMedGoogle Scholar
• 72 Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B.. Improved postoperative outcomes associated with preoperative statin therapy.  Anesthesiology. 2006;  105 1289-90
  CrossrefPubMedGoogle Scholar
• 73 Vogelmeier C. et al. . (Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin).  Pneumologie. 2007;  61 1-40
  Article in Thieme ConnectPubMedGoogle Scholar
• 74 Buhl R. et al. . (Guidelines for diagnosis and treatment of asthma patients).  Pneumologie. 2006;  60 139-77
  PubMedGoogle Scholar
• 75 Ollenschläger G, Kopp I, Lelgemann M.. Die Nationale Versorgungsleitlinie COPD.  Medizinische Klinik. 2007;  102 1615-6722
  PubMedGoogle Scholar
• 76 Mapel DW. et al. . Survival of COPD patients using inhaled corticosteroids and long–acting beta agonists.  Respir Med. 2006;  100 595-609
  CrossrefPubMedGoogle Scholar
• 77 Lelgemann M, Kopp I, Ollenschläger G.. Die Nationale Versorgungsleitlinie Asthma.  Medizinische Klinik. 2005;  101 1615-6722
  PubMedGoogle Scholar
• 78 Knuttgen D, Wappler F.. (Anaesthesia for patients with adrenal gland diseases).  Anasthesiol Intensivmed Notfallmed Schmerzther. 2007;  42 170-8
  PubMedGoogle Scholar
• 79 Scherpereel PA, Tavernier B.. Perioperative care of diabetic patients.  Eur J Anaesthesiol. 2001;  18 277-94
  CrossrefPubMedGoogle Scholar
• 80 Robertshaw HJ, Hall GM.. Diabetes mellitus: anaesthetic management.  Anaesthesia. 2006;  61 1187-90
  CrossrefPubMedGoogle Scholar
• 81 Thorell A. et al. . Surgery–induced insulin resistance in human patients: relation to glucose transport and utilization.  Am J Physiol. 1999;  276 754-61
  PubMedGoogle Scholar
• 82 Van den Berghe G. et al. . Intensive insulin therapy in the critically ill patients.  N Engl J Med. 2001;  345 1359-67
  CrossrefPubMedGoogle Scholar
• 83 Kersten JR, Schmeling TJ, Hettrick DA, Pagel PS, Gross GJ, Warltier DC.. Mechanism of myocardial protection by isoflurane. Role of adenosine triphosphate–regulated potassium (KATP) channels.  Anesthesiology. 1996;  85 794-807
  CrossrefPubMedGoogle Scholar
• 84 Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 854-65
  CrossrefPubMedGoogle Scholar
• 85 Bailey CJ, Turner RC.. Metformin.  N Engl J Med. 1996;  334 574-9
  CrossrefPubMedGoogle Scholar
• 86 Gowardman JR, Havill J.. Fatal metformin induced lactic acidosis: case report.  N Z Med J. 1995;  108 230-1
  PubMedGoogle Scholar
• 87 Mercker SK, Maier C, Neumann G, Wulf H.. Lactic acidosis as a serious perioperative complication of antidiabetic biguanide medication with metformin.  Anesthesiology. 1997;  87 1003-5
  PubMedGoogle Scholar
• 88 Mears SC, Lipsett PA, Brager MD, Riley 3rd. LH. Metformin–associated lactic acidosis after elective cervical spine fusion: a case report.  Spine. 2002;  27 482-4
  CrossrefPubMedGoogle Scholar
• 89 Lalau JD, Race JM.. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin–associated lactic acidosis'.  Diabetes Obes Metab. 2001;  3 195-201
  CrossrefPubMedGoogle Scholar
• 90 Duncan AI. et al. . Recent metformin ingestion does not increase in–hospital morbidity or mortality after cardiac surgery.  Anesth Analg. 2007;  104 42-50
  CrossrefPubMedGoogle Scholar
• 91 Brown JB, Pedula K, Barzilay J, Herson MK, Latare P.. Lactic acidosis rates in type 2 diabetes.  Diabetes Care. 1998;  21 1659-63
  PubMedGoogle Scholar
• 92 Salpeter S, Greyber E, Pasternak G, Salpeter E.. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006
  Google Scholar
• 93 Lalau JD, Race JM.. Lactic acidosis in metformin–treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.  Drug Saf. 1999;  20 377-84
  PubMedGoogle Scholar
• 94 Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB.. Metformin and lactic acidosis: cause or coincidence? A review of case reports.  J Intern Med. 2004;  255 179-87
  CrossrefPubMedGoogle Scholar
• 95 Brilakis ES, Banerjee S, Berger PB.. Perioperative management of patients with coronary stents.  J Am Coll Cardiol. 2007;  49 2145-50
  PubMedGoogle Scholar
• 96 Dalal AR, D'Souza S, Shulman MS.. Brief review: Coronary drug–eluting stents and anesthesia: (Article de synthese court : Les tuteurs coronariens actifs et l'anesthesie).  Can J Anaesth. 2006;  53 1230-1243
  PubMedGoogle Scholar
• 97 Rote Liste.. Frankfurt/Main: Rote Liste Service. 2007
  Google Scholar
• 98 Ruß A.. Arzneimittelpocket. Grünwald: Björm Bruckmeier Verlag 2007
  Google Scholar

Dr. med. Andreas Redel
PD Dr. Ulrich Schwemmer

Email: Redel_A@klinik.uni-wuerzburg.de

Email: Schwemmer_U@klinik.uni-wuerzburg.de

• Supplementary Material